The pace of deals in the pharmaceutical industry shows no sign of slowing and the ones with big bucks, or rather biobucks, grab the headlines. However, the billions of dollars cited in those headlines mask the reality where the upfront fee and the potential value of the deal are almost always poles apart.
How these deals are structured reveals where buying power lies in the sector: the small biotech hopes for the big...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?